Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation.
An intravenous formulation of busulfan, a cytotoxic bifunctional alkylating agent, has been developed to replace oral busulfan as a conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) in pediatric patients. Doses of intravenous busulfan based on actual bodyweight, but not age, reduce inter- and intraindividual variability in exposure. In a study of intravenous busulfan as a conditioning treatment prior to allogeneic or autologous HSCT, the majority of pediatric patients, who received one of five bodyweight-based doses, achieved busulfan area under the plasma concentration-time curve (AUC) values within the targeted therapeutic range. Although mean busulfan clearance values were highly variable between bodyweight strata, exposure was not affected, with no significant differences between bodyweight groups in mean AUC values. The achievement of therapeutic AUC values with intravenous busulfan resulted in a high rate of sustained engraftment, low transplant-related mortality, and promising survival outcomes post-transplant. Intravenous busulfan was considered to be well tolerated, in the particular context of HSCT, and no failure of HSCT due to organ toxicity was reported. Nonhematologic adverse events commonly associated with busulfan conditioning regimens were frequent, but generally of mild to moderate severity. The intravenous busulfan regimen was frequently associated with elevated liver enzymes, but hepatic veno-occlusive disease (HVOD) was infrequent, of mild to moderate severity, and resolved within 10 days of diagnosis. Unlike oral busulfan, intravenous busulfan does not appear to be associated with severe HVOD or death due to organ toxicity.
Hoy
Sheridan M
SM
Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz
Lyseng-Williamson
Katherine A
KA
D000293:Adolescent; D000477:Alkylating Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D019540:Area Under Curve; D002066:Busulfan / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002648:Child; D002675:Child, Preschool; D018849:Controlled Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D000477:Alkylating Agents; D002066:Busulfan
Biol Blood Marrow Transplant. 1999;5(5):306-15
10534061
J Pediatr Hematol Oncol. 2007 Jul;29(7):445-50
17609621
Drug Metab Dispos. 1999 Dec;27(12):1466-9
10570028
J Clin Pharmacol. 2007 Jan;47(1):101-11
17192508
Cancer Res. 1990 Oct 1;50(19):6203-7
2400986
Bone Marrow Transplant. 1997 Dec;20(11):909-13
9422468
Bone Marrow Transplant. 1998 Nov;22(10):989-94
9849696
Oncol Nurs Forum. 2006 Nov 03;33(2):E36-43
16518436
Bone Marrow Transplant. 2004 May;33(10):979-87
15064687
Bone Marrow Transplant. 2000 May;25(9):915-24
10800057
Bone Marrow Transplant. 2000 Nov;26(10):1089-95
11108308
Blood. 1994 Oct 1;84(7):2144-50
7919328
Anticancer Drugs. 2006 Oct;17(9):1099-105
17001185
Med Oncol. 1999 Sep;16(3):166-76
10523796
Cancer Chemother Pharmacol. 2008 Jan;61(1):113-23
17393167
Cancer Res. 1997 Dec 15;57(24):5509-16
9407960
Clin Pharmacokinet. 2000 Aug;39(2):155-65
10976660
Bone Marrow Transplant. 2006 Mar;37(5):439-49
16444286
Biol Blood Marrow Transplant. 2007 Mar;13(3):307-14
17317584
Cancer Chemother Pharmacol. 1996;37(3):247-53
8529285
Bone Marrow Transplant. 2001 Jun;27(11):1121-4
11551021
Bone Marrow Transplant. 2001 Oct;28(8):743-51
11781625
Cancer Chemother Pharmacol. 1989;24(6):386-90
2791192
Bone Marrow Transplant. 1995 Jul;16(1):31-42
7581127
J Clin Oncol. 2007 May 1;25(13):1772-8
17470868
Clin Pharmacokinet. 2006;45(3):305-16
16509762
CMAJ. 2004 May 11;170(10):1569-77
15136552
Bone Marrow Transplant. 2003 Nov;32(10):979-86
14595385
Anticancer Res. 1994 Nov-Dec;14(6A):2363-70
7825973
Anticancer Res. 1996 Jul-Aug;16(4A):2083-8
8712747
Ann Pharmacother. 1994 Sep;28(9):1055-62
7803883
Biol Blood Marrow Transplant. 2004 Nov;10(11):805-12
15505611